This article is more than 5 years old. Information may no longer be current.

Therapy for wet AMD enters phase 1 trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SOUTH SAN FRANCISCO, Calif. — Athenagen Inc. has initiated a phase 1 clinical trial of its ATG003, an investigational topical drug for exudative age-related macular degeneration, the company announced.

ATG003 is a topical formulation of mecamylamine that inhibits endothelial nictonic acetylcholine receptors, according to the company. It has been shown to decrease angiogenesis and vascular permeability, the company said.

The randomized, placebo-controlled, ascending dose trial will evaluate ocular tolerability and safety of the compound for up to 14 days, according to a press release from Athenagen.

This is the first human trial of an eye drop therapy for wet AMD, company officials said in the release.